跳至主要内容
临床试验/NCT00688532
NCT00688532已完成不适用

A Pharmacoepidemiological Study on the Association Between Bicalutamide Treated Prostate Cancer and Risk of Coronary Heart Disease (CHD) and Heart Failure (HF) in the General Practice Research Database (GPRD)

AstraZeneca0 个研究点目标入组 5,103 人开始时间: 2007年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
5,103
主要终点
Heart Failure

研究概览

简要总结

A retrospective cohort study performed in the GPRD,UK. All patients with incident prostate cancer identified between 1 Jan 1999 and 31 Dec 2005 and a frequency-matched cohort of the general population will be followed- up for two outcomes; CHD including acute myocardial infarction or death from coronary heart disease and HF until Dec 31, 2006. Outcomes will be validated through requests to primary care physicians. Incidence rate´ratios of CHD and HF in the two cohorts will be calculated. In the cohort of prostate cancer the relative risk of CHD and HF associated with the use of bicalutamide compared to non-use will be estimated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
50 Years 至 84 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • At least two years enrollment with the general practitioner

排除标准

  • Patients with cancer before start date of the study

结局指标

主要结局

Heart Failure

时间窗: From study start 1 Jan 1999 through 31December 2006

Coronary heart disease including acute myocardial infarction and death from CHD

时间窗: From study start 1 Jan 1999 through 31December 2006

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

相似试验